VisionHealth and Boehringer Ingelheim cooperate on distribution of the inhalation app Kata®. The certified health app Kata® guides and records correct inhalation and therapy delivery for asthma and COPD. A precise use of inhalation devices is vital for successful therapy.
Around 250 million people worldwide suffer from chronic lung diseases. Correct use of the inhaler is a decisive factor in the success of therapy. However, studies show error rates of between 32 and 100 % during application. With incorrect inhalation, less active ingredient reaches the lungs, which can lead to more severe disease progression in the long term. Within daily medical routines, regularly training patients on inhalation devices is often not possible due to low resources.
This is exactly where Munich-based VisionHealth GmbH comes in with its app Kata®. The versatile, easy-to-use application uses a smartphone camera and artificial intelligence (AI) to support precise inhalation, ensuring that the right medication dose reaches the lungs. Kata® then provides feedback via text and images on how well the inhalation was performed. Symptom and daily therapy records support both patients and their physicians in treatment decisions. The app is adapted to the most common inhalation devices and can improve the therapeutic effectiveness in about 75 % of current marketed devices.
VisionHealth GmbH is a pioneer of digital therapy support for respiratory diseases and was founded in 2017. In cooperation with research institutions and selected industry partners, medical experts and IT experts, VisionHealth develops innovative and unique digital health solutions.
As part of the collaboration, Boehringer Ingelheim will be responsible for marketing and sales of the Kata app.
For Martin Beck, Head of Human Pharma Germany at Boehringer Ingelheim, Kata is "the ideal addition to Boehringer Ingelheim's broad inhalation portfolio." In this way, the biopharmaceutical company wants to guarantee patients receive best guidance when using their inhalation devices, thus ensuring active ingredients reach the lungs.
Dr. Sabine Häußermann, CEO of VisionHealth is proud of the collaboration: "With 100 years of experience in treating lung diseases, Boehringer Ingelheim is a world leader in respiratory diseases."